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Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recur-
rence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR
trial
Aims: Beta2-microglobulin (B2M) forms part of the
HLA class I complex and plays a role in metastatic
biology. B2M mutations occur frequently in mis-
match repair-deficient colorectal cancer (dMMR CRC),
with limited data suggesting they may protect against
recurrence. Our experimental study tested this
hypothesis by investigating B2M mutation status and
B2M protein expression and recurrence in patients in
the stage II QUASAR clinical trial.
Methods and results: Sanger sequencing was per-
formed for the three coding exons of B2M on 121
dMMR and a subsample of 108 pMMR tumours; 52
with recurrence and 56 without. B2M protein expres-
sion was assessed by immunohistochemistry. Mutation
status and protein expression were correlated with
recurrence and compared to proficient mismatch repair
(pMMR) CRCs. Deleterious B2M mutations were
detected in 39 of 121 (32%) dMMR tumours. Five
contained missense B2M-variants of unknown signifi-
cance, so were excluded from further analyses. With
median follow-up of 7.4 years, none of the 39 B2M-
mutant tumours recurred, compared with 14 of 77
(18%) B2M-wild-type tumours (P = 0.005); six at local
and eight at distant sites. Sensitivity and specificity of
IHC in detecting B2M mutations was 87 and 71%,
respectively. Significantly (P < 0.0001) fewer (three of
104, 2.9%) of the 108 pMMR CRCs demonstrated dele-
terious B2M mutations. One pMMR tumour, contain-
ing a frameshift mutation, later recurred.
Conclusion: B2M mutations were detected in nearly
one-third of dMMR cancers, none of which recurred.
B2M mutation status has potential clinical utility as
a prognostic biomarker in stage II dMMR CRC. The
mechanism of protection against recurrence and
whether this protection extends to stage III disease
remains unclear.
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Introduction
The mismatch repair system (MMR) is responsible for
recognising and repairing errors during DNA replica-
tion. Defects in this system lead to a hypermutation
state and accumulation of genetic mutations. When
this occurs within tumour suppressor genes or onco-
genes, it predisposes to malignancy. Germline muta-
tions in MMR genes give rise to Lynch syndrome,
characterised by an inherited predisposition to early
onset of tumours.1 Epigenetic silencing of the MLH1
gene (promoter hypermethylation and associated
BRAF mutation) also leads to mismatch repair-defi-
cient (dMMR) tumours, which represent approxi-
mately 15% of colorectal cancers (CRC).2 Two further
proposed mechanisms account for a small proportion
of Lynch syndrome cases; first, the presence of epimu-
tations of MLH1 and secondly the presence of
heterozygous germline deletions of the 3 exons of the
epithelial cell adhesion molecule (EPCAM). The for-
mer is characterised by promoter methylation and
transcriptional silencing of a single allele of a gene in
normal tissues, whereas in the latter, deletion of
EPCAM results in transcriptional read-through, thus
silencing MSH2.3,4
dMMR CRCs are biologically different from CRCs
arising through the chromosomal instability pathway.
They exhibit the characteristic histological appear-
ances of the microsatellite instability phenotype (MSI-
H), including poor differentiation, mucinous histology
and the presence of numerous tumour-infiltrating
lymphocytes.5 In stages II/III disease, dMMR tumours
are associated with a favourable prognosis with
improved survival compared to proficient MMR
(pMMR) tumours.6–10 However, in stage IV CRC,
dMMR is less frequent (3–5%) and is associated with
a significantly worse prognosis.11 dMMR CRCs accu-
mulate somatic mutations in genes which are usually
highly conserved.
Beta2-microglobulin (B2M) is a component of the
human leucocyte antigen (HLA) class I complex,
which is involved in the presentation of antigenic
peptides, at the cell surface, to cytotoxic CD8+ T cells.
The B2M gene contains several coding microsatel-
lites, making it a mutagenic target in the presence of
mismatch repair deficiency.12 Somatic B2M muta-
tions are found in approximately 30% of dMMR
CRCs, but are rare (<2%) in CRCs with proficient mis-
match repair.13–17 In a consecutive series of MSI-H
CRCs, Kloor and colleagues16 detected B2M muta-
tions in 29 of 104 (28%). All B2M mutations
occurred within localised tumours (stages I–III) (23 of
68; 34%), but none occurred in nine CRCs with stage
IV disease (P = 0.04). Kloor et al.16 hypothesised that
functional B2M is important in tumour development
and B2M mutations may protect patients from devel-
oping distant metastases. These findings were repli-
cated in a small cohort of MSI-H CRCs (n = 34) from
the FOGT-4 trial. B2M mutations were identified in
10 of 34 tumours (29%), none of which recurred
during 5 years follow-up (none of 10), while six of
24 (25%) B2M-wild-type MSI-H CRCs recurred
(P = 0.09), all within 12 months of surgery.12 These
studies suggested that B2M mutation status might
provide useful prognostic information, but were
inconclusive because of their small size.
The aim of this study was to determine the fre-
quency of somatic B2M mutations in a sample of
dMMR and pMMR CRC specimens from a large ran-
domised controlled clinical trial (QUASAR) and corre-
late mutation status with B2M protein expression
and recurrence.
Materials and methods
In the QUASAR trial (ISRCTN82375386), patients
with an uncertain indication for chemotherapy fol-
lowing curative CRC resection were randomised to
receive 5-fluorouracil/folinic acid or observation and
followed-up for a median of 5.5 years. A total of
3239 patients were recruited to the study (71% colon
cancer; 29% rectal cancer), with the majority (91%)
having stage II disease. Adjuvant chemotherapy was
associated with better recurrence-free and overall sur-
vival with an absolute survival advantage of 3.6% at
5 years.18
Tumour blocks and DNA samples were obtained
retrospectively for CRCs from the QUASAR trial.
Tumours had previously been characterised as
dMMR, with loss of either MLH1 or MSH2 protein
expression by immunohistochemistry.8 Hutchins and
colleagues investigated the value of mismatch repair
status in predicting recurrence in the QUASAR sam-
ples. Recurrence rates for the 218 of 1913 (11%)
CRCs that had MLH1 or MSH2 loss (dMMR CRC)
were 11% compared with 26% for pMMR tumours
[risk ratio (RR) = 0.53; 95% confidence interval
(CI) = 0.40–0.70; P < 0.001].8
B E T A 2 M I C R O G L O B U L I N M U T A T I O N A N A L Y S I S
The study was approved by the South Manchester
Research Ethics Committee (10/H1003/11). All three
coding exons of the B2M gene were amplified in four
20-µl polymerase chain reactions (PCR) using N13-
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tailed forward and reverse primers (see Supporting
information, Data S1). PCR was performed using a
Veriti 96-well thermal cycler. PCR products were
purified prior to bi-directional BigDye version 3.1
Sanger sequencing using Agencourt AMPure XP
beads and following sequencing Agencourt CleanSeq
beads with a Biomek NX Laboratory Automation
Workstation (Beckman Coulter, High Wycombe, UK).
Sanger sequencing reactions were analysed using a
3730 DNA Analyser (Applied Biosystems, Warring-
ton, UK).
G E N O T Y P I N G
Mutation analysis was performed using trace subtrac-
tion software (Staden package; www.sourceforge.net).
Tumour sequence data were compared against
sequence data from a normal control sample. Muta-
tions and variants were named according to Human
Genome Variation Society nomenclature using the
B2M reference sequence NM_004048.2 (www.hgvs.
org/mutnomen). All mutations and potentially delete-
rious variants were confirmed by sequencing of an
independent PCR amplification. Frameshift and non-
sense mutations within coding regions of B2M exons
and mutations affecting the invariant splice site
(within two base pairs of the flanking intronic
sequence) were considered significant. Synonymous
mutations and intronic mutations were considered to
be insignificant. Missense mutations were considered
variants of uncertain significance and were analysed
separately. The probable effect upon protein expres-
sion and function was predicted using software
within Alamut version 2.2 (Interactive Biosoftware,
Rouen, France). As almost all B2M mutations in CRC
occur within exon 1 and the portion of exon 2 cov-
ered by the 2a amplicon,19 samples were included
even if an analysable result could not be obtained for
the 2b amplicon or exon 3.
I M M U N O H I S T O C H E M I C A L A N A L Y S I S
Tissue microarrays (TMA) containing cores from up
to 42 cases each had previously been constructed.
Three representative cores of tumour tissue plus three
cores of tumour-associated normal tissue were used
per patient (Figure 1).
Immunohistochemistry (IHC) was performed on 5-
m sections from each TMA using the Dako
EnVision + system (Dako, High Wycombe, UK). Slides
B2M negative
Weak staining
Strong staining
Figure 1. A tissue microarray (TMA) containing cores of tumour tissue from 42 colorectal cancers from the QUASAR study, with additional
cores of sheep lung, liver, brain and placenta as orientation markers. Tissue scores were scored as ‘no staining’ (0), ‘weak staining’ (1) or
‘strong staining’ (2)
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were stained with primary antibody to B2M protein
(rabbit polyclonal, NCL-B2Mp; Leica Biosystems, New-
castle upon Tyne, UK) at 1:800 dilution and horse-
radish peroxidise (HRP)-labelled anti-rabbit secondary
antibody. The immunological reaction was visualised
using 3, 3-diaminobenzidine (DAB) as chromogen
and counterstained with haematoxylin. Slides were
scanned at 9 20 magnification and visualised using
Aperio ImageScope software (version 11.1). Tumours
were scored as no staining (0), weak staining (1) or
strong staining (2) by two independent researchers
(P.B., S.D.R.) taking an average score across the three
cores, and disagreements were resolved by consensus
(Figure 1). Positively stained stromal cells were used
as an internal positive control.
S T A T I S T I C A L A N A L Y S I S
A power calculation was based on a 28% B2M muta-
tion frequency in dMMR CRC16 and 20% recurrence
rate within QUASAR.16 At 5% significance level and
80% power, the number of tumours required to
detect 0% and 20% recurrence rates in tumours with
and without a B2M mutation, respectively, was 108.
Mutation analysis was performed blinded to the clini-
cal outcome and results reported to the QUASAR col-
laborative group. Correlation between B2M mutation
status and IHC protein expression and recurrence
was explored using Mantel–Haenszel tests for associa-
tion and log-rank time-to-event analyses. A probabil-
ity of < 0.05 was taken to indicate statistical
significance. For pMMR tumours, the B2M mutation
frequency was predicted to be lower, and therefore
only a subsample were tested in a case–control study
enriched for recurrence. Equal numbers of recurrent
and non-recurrent tumours were selected at random
from the QUASAR database.
Results
B 2 M M U T A T I O N F R E Q U E N C Y
One hundred and forty-seven dMMR CRC samples
were analysed (144 colon, two rectum, one rectosig-
moid); 26 samples failed to amplify or results could
not be confirmed. Verified results were obtained for
121 samples (102 MLH1 loss, 19 MSH2 loss). Thirty-
nine of 121 (32.2%) contained pathogenic B2M
mutations (see Supporting information, Data S2).
Twenty-one samples contained one pathogenic muta-
tion and 18 samples carried more than one. Overall,
58 pathogenic mutations were detected in 39 sam-
ples. Eleven samples contained missense mutations of
uncertain significance, six in conjunction with a
pathogenic B2M mutation (see Supporting informa-
tion, Data S3). There was no significant difference in
B2M mutation frequency based on whether MLH1 or
MSH2 protein expression had been lost (P = 0.46) or
BRAF mutation status (P = 0.87).
Fifty-five of 58 (95%) pathogenic B2M mutations
occurred within exon 1 or exon 2 amplicon 2a, with
the majority of these being frameshift mutations (47
of 58; 81.0%). Most frameshift mutations occurred at
nucleotide repeats (36 of 47; 76.6%), with nearly half
(23 of 47; 48.9%) occurring at a (CT)4 mutational
‘hot-spot’ in exon 1. Fourteen different frameshift
mutations were identified. The most frequent muta-
tion was c.43_44delCT p.(Leu15PhefsTer41), which
was detected in 23 samples.
Seven non-sense mutations were identified which
cause premature termination of the B2M protein.
These occurred throughout all exons of the B2M
gene and were classified as pathogenic. Three splice
site mutations were identified which were predicted
to significantly affect protein expression. One stop
codon mutation was also detected [c.360A> C
p.(Ter120TyrextTer49)].
C O R R E L A T I O N O F B 2 M M U T A T I O N S W I T H B 2 M
P R O T E I N E X P R E S S I O N
B2M protein expression was available for 88 samples
with known B2M mutation status. Protein expression
was assessed independently by P.B. and S.D.R., with
interobserver agreement of 83 of 88 (94%). Of the 23
tumours with pathogenic B2M mutations, 20 (87%)
showed complete loss of B2M expression (sensitivity
87%). Thirteen of 23 (57%) contained two or more
pathogenic B2M mutations and all but one of these
13 had complete loss of B2M expression (12 of 13;
92%). The samples with pathogenic B2M mutations
and no loss of B2M expression on IHC had a frame-
shift mutation in exon 1 (one sample) and non-sense
mutations in exons 1 and 2a (two samples). Of 61
tumours with wild-type B2M, 18 (30%) had complete
loss of B2M expression on IHC (specificity: 70%). All
four samples tested with isolated missense mutations
maintained B2M expression.
E F F E C T O F B 2 M M U T A T I O N S A N D P R O T E I N
E X P R E S S I O N O N R E C U R R E N C E
Five of the 121 dMMR CRCs with isolated missense
variants of uncertain significance were excluded,
leaving 116 tumours for analysis (Figure 2). Thirty-
nine samples had a pathogenic B2M mutation and
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77 had wild-type B2M. With a median of 7.4 years
of follow-up, none of the 39 tumours with significant
B2M mutations recurred compared to 14 of 77
(18.2%) of tumours with wild-type B2M (P = 0.005).
B2M loss via epigenetic mechanisms did not appear
to offer complete protection from recurrence. Three of
18 tumours with B2M protein loss in the presence of
a wild-type B2M gene recurred. In addition, of 26
tumours which failed to amplify, 10 tumours demon-
strated protein loss by IHC, two of which recurred. Of
interest, one of the tumours with an isolated missense
variant recurred.
Of 177 pMMR CRCs tested, 69 failed to amplify so
analysable results were available for 108 pMMR sam-
ples, 52 from recurrent tumours and 56 from non-re-
current tumours. Four missense mutations of
uncertain significance were identified (two recurrent,
two non-recurrent), and were excluded. Significantly
fewer (P < 0.0001) of the pMMR than dMMR CRCs
contained B2M mutations: 2.9% (three of 104) ver-
sus 36% (39 of 108). Two pMMR tumours had fra-
meshift mutations (c.43_44delCT and c.204delA) and
one a splice site mutation (c.68-2A> G). The tumour
containing the commonly found c.43_44delCT frame-
shift mutation recurred.
B2M status was not significantly related to any
tumour characteristics other than MMR status. Similar
proportions of the B2M-mutant and B2M-wild-type
dMMR tumours were T4 stage [18% (seven of 38) ver-
sus 19% (14 of 74)], poorly differentiated [16% (six of
38) versus 19% (14 of 74)], mucinous [26% (10 of 38)
versus 28% (21 of 74)], had KRAS mutations [25%
(nine of 36) versus 25% (18 of 73)], BRAF mutations
[33% (12 of 36) versus 28% (21 of 74)] and high
oncotype DX recurrence scores [28% (10 of 36) versus
27% (17 of 62)]. The B2M-mutant tumours were,
however, less locally invasive with none exhibiting
extramural invasion, significantly fewer than among
the B2M-wild-type tumours: 0% (none of 38) versus
16% (12 of 74), P = 0.009. As 95% (110 of 116) of
the tumours tested were stage II, consistent with the
91% overall proportion of stage II CRCs in QUASAR,
we could not meaningfully compare propensity for
nodal spread in B2M-mutant and wild-type tumours:
2.6% (one of 39) versus 3.9% (three of 77) were node-
positive. With no strong associations between B2M
status and these other variables, comparisons of recur-
rence rates between B2M-mutant and wild-type
tumours adjusting for other variables produced near
identical results to the unstratified analyses (Figure 3).
QUASAR
MMR status
dMMR pMMR
B2M analysis B2M analysis
B2M status
B2M mutation B2M wild-type
B2M mutation B2M mutation
B2M status
104
Recurrence
P = 0.005 P = 0.581
Recurrence
Recurrent Non-recurrent
0% 14 (18.2%)
Excluded:
Failed to amplify: 26
Missense variant: 5
Excluded:
Failed to amplify: 69
Missense variant: 4
218 1695
147 177
116
39 77 50 54
1 (2%) 2 (3.7%)
1913
3239
Figure 2. Consort diagram of samples in the QUASAR study and subsequent studies
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Figure 3. Recurrence by B2M status stratified by chemotherapy allocation, Dukes stage, T-stage, tumour grade, KRAS status, BRAF status
and oncotype DX risk score
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To assess whether the previously reported better
prognosis of MMR-deficient tumours8 might be
explained by their association with B2M mutations,
we compared the recurrence rate in dMMR B2M-
wild-type tumours with that in all MMR-proficient
tumours in the QUASAR trial, and found no signifi-
cant difference overall or in analyses restricted to
right-sided colon tumours, where most dMMR
tumours arise (Figure 4). There were too few recur-
rences in the dMMR B2M-wild-type tumours to assess
whether chemotherapy was equally effective in such
tumours compared to pMMR tumours, but the trend
towards fewer recurrences in the chemotherapy than
control groups [14.3% (six of 42) versus 22.9% (eight
of 35) recurred, risk ratio = 0.56; 95% CI = 0.20–
1.62, 2P = 0.29] (Figure 5) is consistent with equal
efficacy of chemotherapy in this subgroup.
The immune infiltration within each of the 39
B2M-mutant dMMR was assessed by review of the
haematoxylin and eosin (H&E)-stained slides. An
equally sized group of dMMR B2M-wild-type tumours
was selected at random. Infiltration was graded as
‘0’, no infiltration; ‘1’, scattered inflammatory cells;
‘2’, very mild band-like infiltrate with at least one
aggregate; ‘3’, moderate band-like infiltrate with folli-
cles and ‘4’ dense band-like infiltrate. Infiltration was
then dichotomised into ‘low; ‘0–2’ and high; ‘3 and
4’. Within the B2M-mutant group, 38 H&Es were
assessable and of these, 30 (78.9%) showed low infil-
tration. Of the 43 assessable B2M-wild-type tumours,
79.1% (34 of 43) were deemed to show low infiltra-
tion, making the difference between the two groups
non-significant.
Discussion
This study has determined B2M mutation status and
its influence on recurrence in QUASAR, the largest
randomised trial of adjuvant chemotherapy in col-
orectal cancer. Thirty-nine of 121 (32%) of dMMR
CRCs contained deleterious B2M mutations. We have
shown that B2M mutations were strongly associated
with absence of recurrence (none of 39), compared to
14 of 77 (18%) with wild-type B2M over 10 years’
follow-up, a highly statistically significant difference
(P < 0.005).
Three other studies have reported an absence of
recurrence in B2M-mutant dMMR CRC (Table 1).
Only one was prospective within the context of a
randomised trial, but numbers were small
(n = 34).10 Koelzer et al.20 identified B2M loss in 19
of 98 (19.4%) dMMR CRC patients using IHC. There
were no recurrences (none of 19) in patients with
B2M loss, but 14 of 79 (17.7%) in those with main-
tained B2M expression. This was reflected in pro-
longed 5-year survival (91.7% versus 72.1%).20 In
combination with the current study, 91 dMMR
tumours with B2M deficiency did not recur, seven of
which were stage III tumours, compared with 43 of
234 (18.4%) with proficient B2M that did recur. A
log-rank test for the difference in numbers of recur-
rence in B2M mutation/B2M loss and B2M-profi-
cient, stratified by study, yields a v2 of 19.01,
P = 0.00001.
As in previous studies, we found that B2M muta-
tions are rare in pMMR CRC (< 3%), as it is the cod-
ing microsatellites in the B2M gene which are most
vulnerable to mutation in the presence of
dMMR.13,15,17 Koelzer and colleagues20 found a
somewhat higher rate of B2M protein loss among
pMMR tumours (22 of 310; 7%), although three
(14%) of these 22 tumours recurred and no survival
advantage was demonstrated. In our study, signifi-
cant B2M mutations occurred in 2.9% (three of 104)
pMMR CRCs, and the sample containing the most fre-
quent frameshift mutation recurred. We acknowledge
that a higher proportion of pMMR samples failed to
amplify compared to dMMR (39% versus 17%),
although the main reasons for this are technical. The
DNA was extracted many years ago, using an in-
house phenol–chloroform extraction method, which
we suspect to have contributed to the failure to
amplify of so many samples. However, this was unli-
kely to have been influenced by MMR status.
We must acknowledge the limitations of determin-
ing mismatch repair status purely on the basis of only
MLH1 or MSH2 expression. At the time of testing,
MSH6 and PMS2 were not established as routine
biomarkers. It is possible that a small number of
cases, deemed pMMR on the basis of retained MLH1
and MSH2 expression, would actually have shown
loss of one of MSH6 or PMS2 alone; however, this
number would have been extremely low, and did not
warrant restaining each case.
The use of TMAs allowed high throughput and
cost-effective immunohistochemical staining. We
deemed that three 0.6-mm cores, taken at random,
were representative of each individual tumour. As
staining across the three cores from each case was
consistent, we decided that whole section staining
was not required. Tissue from the QUASAR trial is
a limited and valuable clinical trial resource, so
minimising its use by staining the already-made
TMAs was thought to be the most sensible use of
the tissue. We acknowledge that there were a num-
ber of cases where the B2M protein expression was
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd., Histopathology, 75, 236–246.
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not available. This was due primarily to the tissue
cores on the TMA section either falling off the slide
during the staining process or the core having been
sectioned through so often that there was no
longer sufficient tumour tissue remaining to be
analysed.
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Figure 4. Ten-year risk of recurrence for MMR-deficient, B2M-wild-type tumours compared to MMR-proficient tumours in (A) all patients
and (B) right colon tumours only
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Sensitivity of IHC for significant B2M mutations
was 86.9% and specificity was 70.5%. Factors
accounting for this discrepancy may include the per-
sistent expression of B2M epitope in the presence of a
non-sense mutation, particularly if the mutation is in
the distal part of the gene. Conversely, loss of staining
in tumours with wild-type B2M might be due to large
genomic rearrangements not identifiable with Sanger
sequencing, promoter mutations, mutations involving
miRNA recognition sites, low neoplastic cell content
(<20%) or sampling error. In our study, B2M loss via
epigenetic mechanisms did not confer complete pro-
tection from recurrence, as we identified three
tumours with B2M protein loss in the presence of
wild-type B2M which recurred. Intratumour hetero-
geneity remains a considerable challenge, and it may
be that combining DNA from multiple FFPE tumour
blocks would be more effective for B2M testing, as
demonstrated for KRAS.21 Deeper and more expansive
‘next-generation sequencing’ approaches might also
identify a higher proportion of B2M mutations
among dMMR CRCs, but results with formalin-fixed
paraffin-embedded (FFPE) specimens have been vari-
able and would require careful validation.
B 2 M M U T A T I O N S , L O S S O F H L A C L A S S I A N D
R E C U R R E N C E
The mechanism of protection from distant metastases
afforded by somatic B2M mutations is yet to be fully
elucidated. B2M forms an essential part of the HLA
class I complex on the surface of all nucleated cells.
Deleterious B2M mutations lead to loss of HLA class I
expression, which allows tumour cells to avoid recog-
nition by cytotoxic T lymphocytes but activates natu-
ral killer (NK) cells to destroy tumour cells in
circulation, as a result of missing ‘self-recogni-
tion’.13,15,17,22 There is growing evidence that HLA
class I-deficient tumour cells are less likely to estab-
lish distant metastases than HLA class I-proficient
cells. Menon and colleagues23 showed that loss of
HLA class I expression is rare in colorectal
Events/Patients
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Recurrence:
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B2m vildtype
Combined
(0.0%) (0.0%)
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Figure 5. Recurrences by treatment allocation in MMR-deficient tumours with and without B2M mutations
Table 1. Composite results of studies comparing outcome of dMMR CRC based on B2M mutation status
Study Tumour stage
Recurrence/metastases
B2M mutation/B2M loss B2M-proficient
Kloor et al. (2007)
Case–control
58% stages I/II30% stage III12% stage IV 0/23 9/54
Tikidzhieva et al. (2012)
Randomised trial
24% stages I/II76% stage III 0/10 6/24
Koelzer et al. (2012)
Case–control
53% stages I/II47% stage III 0/19 14/79
Current study
Randomised trial
95% stage II5% stage III 0/39 14/77
Total 0/91 43/234
dMMR, mismatch repair-deficient; CRC, colorectal cancer.
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metastases, and concordance of HLA expression
between primary and metastatic lesions is high. In
uveal melanoma, which has many similarities with
dMMR CRC (preferential haematogenous spread to
the liver and similar B2M mutation pattern), loss of
HLA-class I/B2M expression is also associated with
significantly improved survival.24,25 The role of NK
activity and HLA class I loss in the prevention of dis-
tant metastases has been extensively investigated in
uveal melanoma and fibrosarcoma, in both in in-vitro
studies and mouse models.26–29
Kloor et al.16 suggested that B2M mutations might
enable the tumour cells to evade local immune
responses and promote local tumour growth. In our
study, of the 14 recurrences in dMMR B2M wild-type
tumours, six were local, six distant and two both
local and distant. B2M mutations appear to protect
against local as well as distant recurrence, and this
was separately significant (none of 39 versus eight of
77; P = 0.038).
The protective effect of B2M mutations appears to
be limited to dMMR. The presence of hypermutation
stimulates an augmented immune response, as seen
from histopathological examination of dMMR
tumours. In B2M-mutant dMMR tumours, the
immune response is unleashed in the presence of
abnormal class I presentation, but in pMMR the
immune response is less marked, possibly leading to
survival of the metastatic clones. We propose that
B2M testing is a useful adjunct to routine MMR test-
ing and should be incorporated into a bowel tumour-
specific assay in conjunction with MLH1, KRAS,
NRAS and BRAF status to provide an overall recur-
rence risk for individual patients.
We have tested the validity of B2M mutation as a
prognostic biomarker of recurrence in dMMR CRC in
a large prospective randomised clinical trial. Results
indicate that patients with dMMR CRC who have a
B2M mutation are protected from developing recur-
rent disease following resection. B2M status is a more
accurate prognostic marker than MMR status alone,
and the high prevalence of B2M mutations in dMMR
disease may well explain the better prognosis of
dMMR compared to pMMR CRC. Approximately 15%
of all CRC and virtually all patients with Lynch syn-
drome cancers are dMMR, and one-third of these will
also have a somatic B2M mutation. The one patient
with stage III disease in our study did not recur, nor
did six other patients with stage III B2M-mutant
tumours in the only other prospective study.12 If
patients with B2M-mutant stage III dMMR CRC are
also protected from recurrence, B2M mutation status
would have additional clinical utility.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Data S1. Forward and reverse primer sequences
used for B2M PCR reaction. Primers were designed to
avoid polymorphisms and Alu repeats using Primer 3
(http://primer3.ut.ee/ and SNPCheck3 (http://secure.
ngrl.org.uk/SNPcheck). PCR primers were tagged
with an ‘N13’ universal sequencing tail (Forward: 50-
GTAGCGCGACGGCCAGT; Reverse: 50-CAGGGCG-
CAGCGATGAC). Primers were obtained from Sigma-
Aldrich. Thermal cycling conditions were initial
denaturation 2 mins at 96°, denaturation 30 cycles
of 10 secs at 96°, annealing 20 secs at 55°, exten-
sion 4 mins at 60° and hold at 15°.
Data S2. Description and frequency of B2M muta-
tions identified in the QUASAR dMMR CRC samples.
Data S3. Description, frequency and distribution of
missense B2M mutations and predicted in silico effect
of protein structure and function (*occurred in con-
junction with a pathogenic mutation).
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